Arbutus Biopharma Corp (ABUS)
2.59
+0.10
(+4.02%)
USD |
NASDAQ |
Mar 27, 16:00
2.59
0.00 (0.00%)
After-Hours: 20:00
Arbutus Biopharma Cash from Operations (TTM): -85.94M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -85.94M |
September 30, 2023 | -85.63M |
June 30, 2023 | -82.54M |
March 31, 2023 | -83.28M |
December 31, 2022 | -35.36M |
September 30, 2022 | -37.97M |
June 30, 2022 | -35.32M |
March 31, 2022 | -29.03M |
December 31, 2021 | -67.53M |
September 30, 2021 | -62.94M |
June 30, 2021 | -59.08M |
March 31, 2021 | -53.87M |
December 31, 2020 | -51.44M |
September 30, 2020 | -49.78M |
June 30, 2020 | -61.08M |
March 31, 2020 | -69.88M |
December 31, 2019 | -71.01M |
September 30, 2019 | -74.73M |
June 30, 2019 | -64.46M |
March 31, 2019 | -64.48M |
December 31, 2018 | -67.87M |
September 30, 2018 | -61.13M |
June 30, 2018 | -63.61M |
March 31, 2018 | -51.07M |
December 31, 2017 | -48.64M |
Date | Value |
---|---|
September 30, 2017 | -53.12M |
June 30, 2017 | -52.15M |
March 31, 2017 | -63.87M |
December 31, 2016 | -57.88M |
September 30, 2016 | -61.28M |
June 30, 2016 | -49.09M |
March 31, 2016 | -50.08M |
December 31, 2015 | -56.38M |
September 30, 2015 | -45.01M |
June 30, 2015 | -49.21M |
March 31, 2015 | -39.42M |
December 31, 2014 | -12.42M |
September 30, 2014 | -3.008M |
June 30, 2014 | 0.042M |
March 31, 2014 | 5.258M |
December 31, 2013 | -6.737M |
September 30, 2013 | 31.05M |
June 30, 2013 | 33.21M |
March 31, 2013 | 34.33M |
December 31, 2012 | 32.91M |
September 30, 2012 | -7.896M |
June 30, 2012 | -6.442M |
March 31, 2012 | -8.946M |
December 31, 2011 | -7.831M |
September 30, 2011 | -11.17M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-85.94M
Minimum
Dec 2023
-29.03M
Maximum
Mar 2022
-61.27M
Average
-63.70M
Median
Cash from Operations (TTM) Benchmarks
Pacira BioSciences Inc | 154.65M |
Chimerix Inc | -69.09M |
Karyopharm Therapeutics Inc | -92.72M |
Corvus Pharmaceuticals Inc | -23.94M |
Moderna Inc | -3.118B |